JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Prognostic Factors and Survival in Acute Myeloid Leukemia Cases: a Report from the Northeast of Iran
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Prognostic Factors and Survival in Acute Myeloid Leukemia Cases: a Report from the Northeast of Iran
Allahyari, Abolghasem; Tajeri, Tarane; Sadeghi, Masoud;
  PDF(new window)
 Abstract
Background: Acute myeloid leukemia (AML) is a clonal hematopoietic disorder resulting from genetic alterations in normal hematopoietic stem cells. The aim of this study was to evaluate prognostic factors and survival of AML patients in the Northeast of Iran. Materials and Methods: This retrospective study covered 96 patients with AML referred to Emam Reza Hospital, Mashhad city, Iran, from 2009 to 2015. Age, sex, blood group, type of AML, fever, consumption of amphotericin B, cytogenetic forms and survival were analyzed. Also, WBC, hemoglobin and platelet levels were checked. Mean follow-up was 30.5 months (60.4% mortality). Survival was plotted by GraphPad Prism 5 with Log-rank test. Results: The mean age for all AML patients at diagnosis was 40.4 years (range, 17-77 years). Some 42.7% patients were aged <35 years and 40.6% were male. In all patients, 76% had fever and 50% consumed amphotericin. T(15;17)(q22;q21) had the most prevalence (37.7%) compared to other forms. Out of 92 patients, O+(30.4%) was the most common blood group and AML-M5 (28.3%) the most common subtype. There was a significant difference in survival based on WBC and consumption of amphotericin B (P<0.05). Conclusions: WBC level, fever and consumption of amphotericin B proved to be factors for survival of AML patients. The mean age for patients in Iran is lower than other areas in the World and also survival in this study was higher than in other studies.
 Keywords
AML;survival;amphotericin B;WBC;northeastern Iran;
 Language
English
 Cited by
 References
1.
Alavi S, Ashraf H, Rashidi A, et al (2006). Distribution of ABO blood groups in childhood acute leukemia. Pediatr Hematol Oncol, 23, 611-7. crossref(new window)

2.
Alibhai SM, Leach M, Minden MD, et al (2009). Outcomes and quality of care in acute myeloid leukemia over 40 years. Cance, 115, 2903-11. crossref(new window)

3.
Ashrafi F, Shahnazari R, Samimi MA, et al (2013). Results of treatment of acute myeloid leukemia in central part of Iran. Adv Biomed Res, 2, 51. crossref(new window)

4.
Ayremlou P, Razavi SM, Solaymani-Dodaran M, et al (2012). Demographic and prognostic factors of 455 patients with acute leukemia admitted to two referral hospitals in tehran-iran during ten years (2001-2011). Iran J Cancer Prev, 5, 157-63.

5.
Byrd JC, Lawrence D, Arthur DC, et al (1998). Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. Clin Cancer Res, 4, 1235-41.

6.
Cohen PL, Hoyer JD, Kurtin PJ, et al (1998). Acute myeloid leukemia with minimal differentiation. A multiple parameter study. Am J Clin Pathol, 109, 32-8. crossref(new window)

7.
Douer D (2003). The epidemiology of acute promyelocytic leukemia. Best Practice Rea Clinical Haematol, 16, 357-67. crossref(new window)

8.
Eriksson U, Seifert B, Schaffner A (2001). Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ, 322, 579-82. crossref(new window)

9.
Estey E, Dohner H (2006). Acute myeloid leukaemia. Lancet, 368, 1894-907. crossref(new window)

10.
Ghosh S, Shinde SC, Kumaran GS, et al (2003). Haematologic and immunophenotypic profile of acute myeloid leukemia: an experience of tata memorial hospital. Indian J Cancer, 40, 71-6.

11.
Gillis S, Dann EJ, Rund D (1996). Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. Am J Hematol, 51, 26-31. crossref(new window)

12.
Girmenia C, Frustaci AM, Gentile G, et al (2012). Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica, 97, 560-7. crossref(new window)

13.
Hamill RJ (2013). Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs, 73, 919-34. crossref(new window)

14.
Harani MS, Adil SN, Shaikh MU, et al (2005). Frequency of fab subtypes in acute myeloid leukemia patients at Aga Khan University Hospital Karachi. J Ayub Med Coll Abbottabad, 17, 26-9.

15.
Hassan K, Qureshi M, Shafi S, et al (1993). Acute myeloid leukemia-FAB classification and its correlation with clinico-haematological features. J Pak Med Assoc, 43, 200-3.

16.
Heil G, Hoelzer D, Sanz MA, et al (1997). A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood, 90, 4710-8.

17.
Juliusson G, Antunovic P, Derolf A, et al (2009). Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood, 113, 4179-87. crossref(new window)

18.
Lerch E, Espeli V, Zucca E, et al (2009). Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland. Tumori, 95, 303-10. crossref(new window)

19.
Mazloumi SH, Kumari P, Madhumathi DS, et al (2012). Rare and recurrent chromosomal abnormalities and their clinical relevance in pediatric acute leukemia of south Indian population. Indian J Med Paediatr Oncol, 33, 166-9. crossref(new window)

20.
Merkel D, Filanovsky K, Gafter-Gvili A, et al (2013). Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol, 88, 130-4. crossref(new window)

21.
Mrozek K (2008). Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol, 35, 365-77. crossref(new window)

22.
Oran B, Weisdorf DJ (2012). Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica, 97, 1916-24. crossref(new window)

23.
Pedersen-Bjergaard J, Andersen MK, Johansson B (1998). Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol, 16, 1897-8. crossref(new window)

24.
Pulsoni A, Pagano L, Latagliata R, et al (2004). Survival of elderly patients with acute myeloid leukemia. Haematologica, 89, 296-302.

25.
Sepehrizadeh Z, Mohammadi M, Emami A, et al (2014). Assessment of cytokine expression profile in acute myeloid leukemia patients before and after chemotherapy. Turk J Haematol, 31, 149-54. crossref(new window)

26.
Shipley JL, Butera JN (2009). Acute myelogenous leukemia. Exp Hematol, 37, 649-58. crossref(new window)

27.
Spitzer TR, Creger RJ, Fox RM, et al (1989). Rapid infusion amphotericin B: effective and well-tolerated therapy for neutropenic fever. Pharmatherapeutica, 5, 305-11.

28.
Stone RM, O’Donnell MR, Sekeres MA (2004). Acute myeloid leukemia. Hematol Am Soc Hematol Educ Program. 2004, 98-117.

29.
Strom SS, Oum R, Elhor Gbito KY, et al (2012). De novo acute myeloid leukemia risk factors: a Texas case-control study. Cancer, 118, 4589-96. crossref(new window)

30.
Vadivelu MK, Damodaran S, Solomon J, et al (2004). Distribution of ABO blood groups in acute leukaemias and lymphomas. Ann Hematol, 83, 584-7.

31.
Walter RB, Othus M, Burnett AK, et al (2013). Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood, 121, 2424-31. crossref(new window)

32.
Ziaei JE (2004). High frequency of acute promyelocytic leukemia in northwest Iran. Asian Pac J Cancer Prev, 5, 188-9.